Stock LEGN LEGEND BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Legend Biotech Corporation

Equities

LEGN

US52490G1022

Real-time Estimate Cboe BZX
Other stock markets
 02:39:26 2024-05-13 pm EDT 		5-day change 1st Jan Change
43.18 USD -0.14% Intraday chart for Legend Biotech Corporation -4.53% -28.19%
03:32pm Sector Update: Health Care Stocks Decline Pre-Bell Monday MT
03:11pm Sector Update: Health Care MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Decline Pre-Bell Monday
Sector Update: Health Care
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
US FDA mandates label updates on CAR-T cancer therapies
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
U.S. FDA approves expanded use of J&J's cancer cell therapy
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
U.S. FDA allows expanded use of Bristol Myers' cell therapy
Legend Biotech Files Mixed-Securities Shelf Registration
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
Sector Update: Health Care Stocks Lean Lower Premarket Monday
Legend Biotech Corporation Announces Management Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW